Prevalence of AmpC and SHV β-lactamases in clinical isolates of Escherichia coli from Tehran hospitals

Jundishapur Journal of Microbiology

Volumn 6, Issue 2, 2013, Pages 176-180

  Soltan Dallal, Mohammad ^a,b   Sabbaghi, Ailar ^b   Molla Aghamirzaeie, Hedrosha ^b   Rastegar Lari, Abdol ^b   Reza Eshraghian, Mohammad ^a   Fallah Mehrabad, Jalil ^c   Rajabi, Zahra ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Bioinformatics Institute   (Iran)

Author keywords

AmpC; Beta Lactamases; SHV type extended spectrum beta lactamases

Indexed keywords

AMOXICILLIN; BETA LACTAMASE AMPC; BETA LACTAMASE SHV; CEFOTAXIME; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLAVULANIC ACID; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; NALIDIXIC ACID; STREPTOMYCIN;

AMPC GENE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BLACITM GENE; BLASHV GENE; BLOOD CULTURE; COMBINED DISK ASSAY; CONTROLLED STUDY; DISK DIFFUSION; ENZYME ANALYSIS; ENZYME SYNTHESIS; ESCHERICHIA COLI; FECES CULTURE; FOX GENE; GENETIC ANALYSIS; HOSPITAL; IRAN; MICROBIOLOGICAL EXAMINATION; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PREVALENCE; SEQUENCE ALIGNMENT; URINE CULTURE; WOUND;

EID: 84877308950     PISSN: 20083645     EISSN: 20084161     Source Type: Journal    
DOI: 10.5812/jjm.5043     Document Type: Article

References (28)

1. Bakhtiari R, Fallah Mehrabadi J, Molla Agamirzaei H, Sabbaghi A, Soltan Dallal MM. Evaluation of extended spectrum beta lactamase enzymes prevalence in clinical isolates of Escherichia coli. Microbiol Res.2011;2(8e):30-32.
2. Rayamajhi N, Kang SG, Lee DY, Kang ML, Lee SI, Park KY, et al. Characterization of TEM-, SHV- and AmpC-type beta-lactamases from cephalosporin-resistant Enterobacteriaceae isolated from swine. Int J Food Microbiol. 2008;124(2):183-187.
3. Ahmed MO, Clegg PD, Williams NJ, Baptiste KE, Bennett M. Antimicrobial resistance in equine faecal Escherichia coli isolates from North West England. Ann Clin Microbiol Antimicrob. 2010;9(12).
4. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001;14(4):933-951.
5. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657-86.
6. Netzel TC, Jindani I, Hanson N, Turner BM, Smith L, Rand KH. The AmpC inhibitor, Syn2190, can be used to reveal extended-spectrum beta-lactamases in Escherichia coli. Diagn Microbiol Infect Dis. 2007;58(3):345-348.
7. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern Lancet Infect Dis. 2008;8(3):159-166.
8. Sturenburg E, Mack D. Extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control. J Infect. 2003;47(4):273-295.
9. Deshpande LM, Jones RN, Fritsche TR, Sader HS. Occurrence of plasmidic AmpC type beta-lactamase-mediated resistance in Escherichia coli: report from the SENTRY Antimicrobial Surveillance Program (North America, 2004). Int J Antimicrob Agents. 2006;28(6):578-581.
10. Goossens H, Grabein B. Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004). Diagn Microbiol Infect Dis. 2005;53(4):257-264.
11. Jacoby GA, Medeiros AA. More extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1991;35(9):1697-1704.
12. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testingClinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing 17th informational supplement. M100-S17. 2007.
13. Song W, Bae K, Lee Y-N, Lee C-H, Lee SH, Jeong SH. Detection of extended-spectrum β -lactamases by using Boronic acid as an AmpC β -lactamase inhibitor in clinical isolates of Klebsiella spp. and Escherichia coli. J Clin Microbiol. 2007;45(4):1180-1184.
14. Coudron PE, Moland ES, Thomson KS. Occurrence and detection of AmpC beta-lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates at a veterans medical center. J Clin Microbiol. 2000;38(5):1791-1796.
15. Al-Jasser AM. Extended-spectrum beta-lactamases (ESBLs): a global problem. Kuwait Med J. 2006;38(3):171-185.
16. Sabate M, Miro E, Navarro F, Verges C, Aliaga R, Mirelis B, et al. Beta-lactamases involved in resistance to broad-spectrum cephalosporins in Escherichia coli and Klebsiella spp. clinical isolates collected between 1994 and 1996, in Barcelona (Spain). J Antimicrob Chemother. 2002;49(6):989-997.
17. Kenny MJ, Birtles RJ, Day MJ, Shaw SE. Community transmission of extended-spectrum β-lactamase. Emerg Infect Dis. 2003;9(8):1024-1025.
18. Hanson ND. AmpC beta-lactamases: what do we need to know for the future? J Antimicrob Chemother. 2003;52(1):2-4.
19. Paterson DL, Ko WC, Von GA, Casellas JM, Mulazimoglu L, Klugman KP. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β -lactamases: Implications for the clinical microbiology laboratory. J Clin Microbiol. 2001;39(6):2206-2212.
20. Walther-Rasmussen J, Hoiby N. Plasmid-borne AmpC beta-lactamases. Can J Microbiol. 2002;48(6):479-493.
21. Zhang Z, Guo X, Zhang Q. Prevalence characterization of extended-spectrum β-lactamases among Escherichia coli isolates collected in Zhengzhou. J Clin Lab analys. 2009;23(6):404-407.
22. Fang H, Ataker F, Hedin G, Dornbusch K. Molecular epidemiology of extended-spectrum beta-lactamases among Escherichia coli isolates collected in a Swedish hospital and its associated health care facilities from 2001 to 2006. J Clin Microbiol. 2008;46(2):707-712.
23. Kim J, Lee HJ. Rapid discriminatory detection of genes coding for SHV beta-lactamases by ligase chain reaction. Antimicrob Agents Chemother. 2000;44(7):18-604.
24. Kiratisin P, Apisarnthanarak A, Laesripa C, Saifon P. Molecular characterization and epidemiology of extended-spectrum- β -lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing Health Care-Associated infection in Thailand, where the CTX-M family is endemic. Antimicrob Agents Chemother. 2008;52(8):2818-2824.
25. Romero ED, Padilla TP, Hernandez AH, Grande RP, Vazquez MF, Garcia IG. Prevalence of clinical isolates of Escherichia coli and Klebsiellaspp. producing multiple extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis. 59(4):433-437.
26. Hosoglu S, Gundes S, Kolayli F, Karadenizli A, Demirdag K, Gunaydin M. Extended-spectrum beta-lactamases in ceftazidime-resistant Escherichia coli and Klebsiella pneumoniae isolates in Turkish hospitals. Indian J Med Microbiol. 2007;25(4):346-50.
27. Thomson KS. Controversies about extended-spectrum and AmpC beta-lactamases. Emerg Infect Dis. 2001;7(2):333-6.
28. Jeong HS, Bae IK, Shin JH, Jung HJ, Kim SH, Lee JY, et al. Prevalence of plasmid-mediated quinolone resistance and its association with extended-spectrum beta-lactamase and AmpC beta-lactamase in Enterobacteriaceae. Korean J Lab Med. 2011;31(4):257-64.